Anti-cancer agents in medicinal chemistry
Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress.
Amiya Das, Viney Lather
Published: 202610.2174/0118715206402646251115102627
Abstract
INTRODUCTION: Triple Negative Breast Cancer (TNBC), which makes up 15% of all breast cancers, is widely acknowledged as the most aggressive and challenging subtype of the disease. It is characterized by the absence of HER2 receptors, progesterone, an…
Preview only. Read the full abstract at the source